Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-19
2009-12-29
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S318000, C546S118000, C546S194000
Reexamination Certificate
active
07638531
ABSTRACT:
Disclosed are compounds of the formulaor a pharmaceutically acceptable salt or solvate thereof, wherein:M is CH or N;U and W are each CH, or one of U and W is CH and the other is N;X is a bond, alkylene, —C(O)—, —C(N—OR5)—, —C(N—OR5)—CH(R6)—, —CH(R6)—C(N—OR5)—, —O—, —OCH2—, —CH2O— or —S(O)0-2—;Y is —O—, —(CH2)2—, —C(═O)—, —C(═NOR7)— or —SO0-2—;Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group;R1is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof;R2is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl;and the remaining variables are as defined in the specification;compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combination with other agents.
REFERENCES:
patent: 5242924 (1993-09-01), Diana
patent: 5364865 (1994-11-01), Diana
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 6720328 (2004-04-01), Aslanian et al.
patent: 6849621 (2005-02-01), Rosenblum et al.
patent: 2004/0019039 (2004-01-01), Dorwald et al.
patent: 2004/0019099 (2004-01-01), Aslanian et al.
patent: 2004/0048843 (2004-03-01), Ting et al.
patent: 2004/0097483 (2004-05-01), Zeng et al.
patent: 2004/0224953 (2004-11-01), Cowart et al.
patent: 0 157 145 (1985-10-01), None
patent: WO 03/088967 (2003-10-01), None
patent: 2004/069816 (2004-08-01), None
patent: WO 2004/089373 (2004-10-01), None
patent: WO 2004/101546 (2004-11-01), None
patent: 2005/012293 (2005-02-01), None
patent: WO 2006/124748 (2006-11-01), None
Hancock et al., “Cognitive enhancing effects of drugs that target histamine receptors”,Cognitive Enhancing Drugs,Edited by J. J. Buccafusco, Birkhauser, Basel pp. 97-114 (2004).
Ley et al., “A Rapid Approach for the Optimisation of Polymer Supported Reagents in Synthesis”, Synlett, 11:1603-1607 (2000).
Leurs et al., “The Histamine H3Receptor: From Gene Cloning to H3Receptor Drugs”,Nature Reviews DrugDiscovery, 4(2):107-120 (Feb. 2005).
Morgan et al., “Synthesis and Cardiac Electrophysiological Activity of N-Substituted-4-(1H-imidazol-1-yl) benzamides—New Selective Case III Agents”,J. Med. Chem.,33:1091-1097 (1990).
Tashiro et al., “Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain”,Life Sciences,72:409-414 (2002).
International Search Report for corresponding PCT Application No. PCT/US2006/1048349 dated Aug. 1, 2007.
Aslanian Robert G.
Berlin Michael Y.
Biju Purakkattle
Boyce Christopher W.
de Lera Ruiz Manuel
Bergman Jeffrey P.
Rahmani Niloofar
Schering Corporation
Seaman D. Margaret
LandOfFree
Phenoxypiperidines and analogs thereof useful as histamine H... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenoxypiperidines and analogs thereof useful as histamine H..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenoxypiperidines and analogs thereof useful as histamine H... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4101407